Alcuni pazienti sembrano tollerare bene il farmaco, ma molti non ne sopportano gli effetti collaterali. Questo aggiunto al fatto che l'obiettivo dichiarato del farmaco non è la guarigione, ma il semplice rallentamento della malattia, mirando ad allungare la vita dei pazienti di alcune settimane.
Molti Oncologi sostengono che non ci siano alternative, ma in questo blog e sul sito www.redonda.it potrete trovare alternative molto valide e, sicuramente, meno dolorose.
Il prodotto da nome commerciale Synchro-Levels (che costa 30 euro circa, contro i 5000 euro (!!!) di Nexavar) ha già dimostrato in alcuni studi e nell'esperienza di importanti ospedali pubblici italiani di funzionare MEGLIO E SENZA EFFETTI COLLATERALI.
Se avete avuto esperienza con Nexavar/Sorafenib, raccontatecela e ricordate che non è l'unica soluzione.
Non abbiate paura a spiegare al vostro oncologo di Synchro-Levels, l'associazione Redonda-Onlus vi aiuterà, se lo vorrete, a reperire il materiale scientifico per spiegare nel dettaglio il suo funzionamento al vostro specialista.
Sorafenib/nexavar is not the unique way of fighting against liver cancer. There is another, SCIENTIFIC, DEMONSTRATED, PER REVIEWED, INTERNATIONALLY PUBLISHED way. Is the stem cells differentiating factors. See www.redonda.it in the scientific pages ("articoli scientifici"), where you can find english scientific papers you can download and show your doctor. Many peoples in Italy are getting better and better. Not everybody, of course, but nobody suffers with terrible side effects.
Write us for any question, we are an independent charity faghitng against cancer and cancer-related lies.
The UK National Institute for Health and Clinical Excellence (NICE) has ruled that sorafenib should not be made routinely available for patients with the most common form of primary liver cancer, advanced hepatocellular carcinoma (HCC).
The institute's appraisal committee reviewed research that has been conducted on the drug and concluded that it does not represent a cost-effective use of NHS resources.
The results of a large-scale clinical trial found that sorafenib is helpful for patients who have not benefited from surgery, or for whom surgery is not a suitable option.
At present, surgery is the only treatment that can actually cure HCC, but most patients are not eligible. Sorafenib can help extend the lives of people with HCC by many weeks, but it is not a cure.
Andrew Dillon, chief executive of NICE, insisted that the institute is disappointed not to have been able to recommend sorafenib for patients with HCC, but that: "After carefully considering all the evidence, including the proposed 'patient access scheme' in which the manufacturer offered to provide every fourth pack free, sorafenib does not provide enough benefit to patients to justify its high cost."
Mr Dillon noted that a greater number of high-cost treatments are now being recommended thanks to NICE's new approach to appraising drugs that extend life.
"We looked at sorafenib in just the same way, but the price being asked by Bayer is simply too high to justify using NHS money which could be spent on better value cancer treatments," he claimed.
Professor Peter Johnson, Cancer Research UK's chief clinician, expressed the charity's disappointment with the decision.
"This drug has an effect in people with advanced liver cancer who are unable to have surgery or any other treatments, so we are disappointed that the manufacturers have been unable to reach an agreement to enable NICE to recommend this drug," he said.
Professor Johnson also noted: "It is particularly frustrating that cancer patients in the UK are unable to access this drug when it is routinely available elsewhere in the world."
Nessun commento:
Posta un commento